Cencora, Inc. (NYSE:COR) Holdings Trimmed by Lincoln Capital Corp

Lincoln Capital Corp trimmed its holdings in Cencora, Inc. (NYSE:COR) by 1.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 22,943 shares of the company’s stock after selling 315 shares during the quarter. Cencora accounts for about 2.1% of Lincoln Capital Corp’s portfolio, making the stock its 17th biggest holding. Lincoln Capital Corp’s holdings in Cencora were worth $5,155,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Public Sector Pension Investment Board raised its holdings in Cencora by 39.4% during the 2nd quarter. Public Sector Pension Investment Board now owns 4,508 shares of the company’s stock worth $1,016,000 after buying an additional 1,274 shares during the period. Evergreen Capital Management LLC lifted its holdings in shares of Cencora by 4.7% in the second quarter. Evergreen Capital Management LLC now owns 1,147 shares of the company’s stock valued at $258,000 after purchasing an additional 52 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Cencora in the second quarter worth $1,539,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its holdings in shares of Cencora by 68.8% during the second quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 34,386 shares of the company’s stock valued at $7,747,000 after buying an additional 14,017 shares in the last quarter. Finally, AXA S.A. raised its position in Cencora by 47.0% during the second quarter. AXA S.A. now owns 251,781 shares of the company’s stock valued at $56,726,000 after buying an additional 80,540 shares during the period. Institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

NYSE COR opened at $247.84 on Friday. The company has a market cap of $47.90 billion, a P/E ratio of 33.00, a P/E/G ratio of 1.53 and a beta of 0.49. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $253.27. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84. The company has a fifty day simple moving average of $237.26 and a 200 day simple moving average of $234.40.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, November 15th. This is a positive change from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.89%. Cencora’s payout ratio is presently 29.29%.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total value of $5,208,619.44. Following the sale, the chairman now directly owns 306,752 shares in the company, valued at $74,283,064.32. This trade represents a 6.55 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the firm’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the transaction, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at $4,649,648.88. The trade was a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 73,187 shares of company stock valued at $17,790,912. Insiders own 15.80% of the company’s stock.

Analyst Ratings Changes

COR has been the topic of a number of research reports. Leerink Partners dropped their target price on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. Robert W. Baird upped their price objective on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Mizuho initiated coverage on shares of Cencora in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price for the company. Barclays boosted their price target on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Finally, UBS Group lifted their price objective on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.60.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.